206 related articles for article (PubMed ID: 11240612)
1. The future of plasma-derived clotting factor concentrates.
Hoots WK
Haemophilia; 2001 Jan; 7 Suppl 1():4-9. PubMed ID: 11240612
[TBL] [Abstract][Full Text] [Related]
2. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A.
Kevane B; O'Connell N
Transfus Apher Sci; 2018 Aug; 57(4):502-506. PubMed ID: 30107983
[TBL] [Abstract][Full Text] [Related]
3. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
Josephson CD; Abshire TC
Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
[TBL] [Abstract][Full Text] [Related]
4. Current therapy for rare factor deficiencies.
Di Paola J; Nugent D; Young G
Haemophilia; 2001 Jan; 7 Suppl 1():16-22. PubMed ID: 11240614
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
6. Clinical issues in inhibitors.
Astermark J; Santagostino E; Keith Hoots W
Haemophilia; 2010 Jul; 16 Suppl 5():54-60. PubMed ID: 20590857
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
Ghosh K; Ghosh K
Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
[TBL] [Abstract][Full Text] [Related]
8. Choice of factor concentrates for haemophilia: a developing world perspective.
Srivastava A
Haemophilia; 2001 Jan; 7(1):117-22. PubMed ID: 11136393
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
10. New-generation recombinant factor concentrates: bridge to gene therapy.
Ragni MV
Haemophilia; 2001 Jan; 7 Suppl 1():28-35. PubMed ID: 11240616
[TBL] [Abstract][Full Text] [Related]
11. The safety of plasma-derived haemophilia factor concentrates - comments on "Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates" Nunes Valença I et al. (2021). Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates. Haemophilia. https://doi.org/10.1111/hae.14382.
Farrugia A
Haemophilia; 2021 Nov; 27(6):e760-e761. PubMed ID: 34455649
[No Abstract] [Full Text] [Related]
12. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
[TBL] [Abstract][Full Text] [Related]
13. Factor concentrates for haemophilia in the developing world.
Bird A; Isarangkura P; Almagro D; Gonzaga A; Srivastava A
Haemophilia; 1998 Jul; 4(4):481-5. PubMed ID: 9873778
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of haemophilia A.
Gringeri A; Muça-Perja M; Mangiafico L; von Mackensen S
Expert Opin Biol Ther; 2011 Aug; 11(8):1039-53. PubMed ID: 21682657
[TBL] [Abstract][Full Text] [Related]
15. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
16. Safety issues affecting hemophilia products.
Hoots WK
Transfus Med Rev; 2001 Apr; 15(2 Suppl 1):11-9. PubMed ID: 11441416
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
Coppola A; Franchini M; Makris M; Santagostino E; Di Minno G; Mannucci PM
Haemophilia; 2012 May; 18(3):e173-87. PubMed ID: 22335611
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
19. Advances in clotting factor treatment for congenital hemorrhagic disorders.
Tarantino MD; Aledort LM
Clin Adv Hematol Oncol; 2004 Jun; 2(6):363-8. PubMed ID: 16163206
[TBL] [Abstract][Full Text] [Related]
20. [Clotting factor concentrates].
Barthels M; Oldenburg J
Hamostaseologie; 2008 Dec; 28(5):387-99. PubMed ID: 19132169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
